Abstracts for rHEALTH’s Factor VIII and Platelet Tests Accepted for Poster and Oral Presentations at Upcoming AACC 2019 Meeting

rHEALTH tests to be presented at the industry’s leading annual conference for laboratory medicine

CAMBRIDGE, Mass., July 10, 2019 – rHEALTH LLC, and its affiliate DNA Medicine Institute, Inc., today announced that both of its abstracts have been accepted via peer-review from for the 2019 American Association of Clinical Chemistry (AACC) meeting.  The titles and details of the abstracts are as follows:

·        Point-of-Care FVIII Test Using an Integrated Microfluidic Consumable with a Fluorogenic Assay, (Poster A-293) on August 6, 2019 at 9:30 AM, Session 07 Hematology and Coagulation

·        Point-of-Care Microvolume Cytometer Measures Platelet Counts with High Accuracy from Capillary Blood, Invited Oral Presentation on August 6, 2019 from 2:15 – 2:30 PM

“We are pleased with the acceptance of these abstracts and look forward to sharing our results with the lab medicine community.  Our work shows that two very different and complex laboratory tests can be implemented at the point-of-care with high performance using the rHEALTH technology,” stated Dr. Eugene Chan, President and CEO.

A point-of-care FVIII test would allow hemophilia A patients and providers to prevent breakthrough bleeding and early detection of inhibitors.  Similarly, an accessible test for platelets can allow proper management of thrombocytopenia, a significant side effect of certain drugs or immune disorders.

The rHEALTH blood sensor technology is an award-winning and patented point-of-care technology that has successfully received funding from the National Aeronautics and Space Administration, National Institutes of Health, and XPRIZE.  It is currently the subject of multiple collaborations with academia and biopharmaceutical companies.  The technology is designed to analyze blood from fingerpricks and generate results in less than 30 minutes for use by consumers and medical professionals.

The 2019 AACC Annual Scientific Meeting & Clinical Lab Expo is the 71st annual conference of the lab medicine community and expects to have over 20,000 professionals in attendance.  It will showcase cutting-edge science and technology and will be held in Anaheim, California, from August 4-8.

About rHEALTH®

rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology.  rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application.  For more information, visit www.rhealth.com.

About DNA Medicine Institute

DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its technology is subject of work funded by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.

Media Contact
Rebecca Yu, (617) 913-7630, pr@rhealth.com

rHEALTH Technology Receives Notice of Allowance from US Patent Office for Multiplexed Tests in Small Sample Volumes

This patent enables rHEALTH’s unique technology to measure many analytes in a given small volume sample at home or in the clinic

CAMBRIDGE, Mass., January 23, 2019 /PRWeb/ -- rHEALTH LLC, an innovative digital health solutions company, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/682,010, entitled “Microparticle Multiplexing” filed by its affiliate company, DNA Medicine Institute (DMI). This application covers the addition of a length scale to hydrogel microparticles.  A Notice of Allowance is a written notification from USPTO that review of the patent application has completed and issuance of the patent is pending. rHEALTH expects the patent to be issued within two months.

“In combination with our US Patent 9,568,425 “Multicoded Analytical Nanostrips,” our technology for highly multiplexed diagnostic tests in small sample volumes now has even broader patent protection,” said Dr. Eugene Y. Chan, Founder and CEO. “The fundamental aspects of this patent enable our unique technology to measure many analytes in a given small volume of sample at home or in the clinic.” 

About rHEALTH

rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.

About DNA Medicine Institute

rHEALTH’s affiliate, DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.

Media Contact
John Adamou

VP, Corporate & Business Development / Media Relations

(617) 999-8395

pr@rhealth.com

rHEALTH Technology Receives Notice of Allowance for New U.S. Patent Covering Small Volume Sample Consumable and Loader

CAMBRIDGE, Mass., Oct. 4, 2018 /PRNewswire-iReach/ -- rHEALTH LLC, an innovative digital health solutions company, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/645,388, entitled “Sample Consumable and Loader” filed by its affiliate company, DNA Medicine Institute (DMI). This application covers the consumable that carries a microvolume of sample to a sample loader to increase reproducibility of sample loading and offers ease-of-use.  A Notice of Allowance is a written notification from USPTO that review of the patent application has completed and issuance of the patent is pending. rHEALTH expects the patent to be issued within two months.

“This Notice of Allowance is an important milestone as we continue to execute against our patent strategy in our effort to develop better care through innovation in portable diagnostic and monitoring technologies”, said Dr. Eugene Y. Chan, Founder and CEO. “The fundamental aspects of this patent enable our consumable technology that carries a small volume of sample possible at point-of-care.” 

About rHEALTH

rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.

About DNA Medicine Institute

rHEALTH’s affiliate, DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.

Media Contact
John Adamou

Vice President, Corporate and Business Development and Media Relations

(617) 999-8395

pr@rhealth.com

rHEALTH Technology Awarded in NASA’s Civilian Commercialization Readiness Pilot Program (CCRPP)

CAMBRIDGE, Mass., Aug. 20, 2018 -- DNA Medicine Institute, Inc., and its affiliate rHEALTH LLC, a digital health solutions company, today announced that the rHEALTH technology is a subject of NASA’s Civilian Commercial Readiness Pilot Program (CCRPP). Recipients of CCRPP awards must not only demonstrate maturation of technology that aligns with NASA interests, but also strong potential use in markets outside of NASA. This competitive award comes after successful completion of Phase I and Phase II of Small Business Innovation Research (SBIR) and Small Technology Transfer (STTR) Programs.

"We are honored and thrilled to continue our collaboration with NASA to deliver a flight-ready prototype of our unique diagnostic and monitoring technology to the International Space Station,” stated Dr. Eugene Chan, President and CEO.

The main project goal is enabling point-of-patient care in space medicine through delivering portable wireless health solutions—including the rHEALTH small volume blood analyzer and the SKYE Sensor vitals monitor—to astronauts working in the International Space Station.

About rHEALTH

rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.

About DNA Medicine Institute

DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.

Media Contact
Lillian Li

(617) 913-7630

pr@rhealth.com

rHEALTH Technology Issued New Patent For Vital Sign Instrument Design

CAMBRIDGE, Mass., March 27, 2018 - rHEALTH LLC announces the issuance of a new patent in the United States for instrument industrial design filed by DNA Medicine Institute, DMI. The design contributes to the diverse measurement capabilities of the rHEALTH digital health platform, which represents broad innovations in testing technologies.

The U.S. Patent and Trademark Office has granted the patent number D814,042, “Vital sign instrument,” for an integrated vital sign monitoring system for non-invasive, wireless, and continuous use. This new design patent highlights the companies’ expanding intellectual property portfolio, demonstrating DMI and rHEALTH’s ongoing commitment to bring better care through innovation in portable diagnostics and monitoring technologies.

About rHEALTH

rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.

About DNA Medicine Institute

DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.

Media Contact
Lillian Li

(617) 913-7630

pr@rhealth.com

rHEALTH Technology in Partnership with NASA and USAF

CAMBRIDGE, Mass., Feb. 6, 2018 -- DNA Medicine Institute, Inc., and its affiliate rHEALTH LLC, a digital health solutions company, today announced that the rHEALTH technology is the subject of a partnership with the National Aeronautics and Space Administration (NASA) and the United States Air Force (USAF). This is done via Phase IIE and III contracts associated with the Small Business Innovation Research (SBIR) and Small Technology Transfer (STTR) Programs.

"We are excited to continue work with NASA and the USAF to implement our unique diagnostic and monitoring technology and the use of the rHEALTH system," stated Dr. Eugene Chan, President and CEO.

The collaboration will focus on advancing portable, wireless monitoring devices, including the rHEALTH small volume blood analyzer and the SKYE Sensor vitals monitor for astronaut and airmen-related applications.

About rHEALTH

rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH's innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.

About DNA Medicine Institute

DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, USAF, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.

Media Contact: Lillian Li, rHEALTH LLC, (617) 913-7630, pr@rhealth.com

rHEALTH Achieves CE Mark for its Factor VIII Test Kit

Cambridge, Mass., January 8, 2018 – rHEALTH LLC., today announces CE marking of its Fluorogenic Factor VIII (FVIII) Test Kit*.  It has met the requirements of CD 98/79/EEC (the European IVD Directive) and is pleased to affix the CE Mark to its rHEALTH Fluorogenic FVIII Kit for Professional Use Only.

The rHEALTH Fluorogenic FVIII Kit is a diagnostic assay intended to quantify the amount Factor VIII levels in human plasma. The assay may be used to aid in the identification of FVIII-deficient patients eligible for treatment for targeted therapeutics, such as anti-hemophilic factor therapies, and may also be used for monitoring the Factor VIII levels of patients using such products. Importantly, the new rHEALTH Fluorogenic FVIII kit offers a method that requires fewer steps compared to similarly sensitive factor assays—which traditionally have complicated protocols with multiple steps. The kit is compatible with the rHEALTH diagnostic platform technology†.

Characterized by deficiency in clotting factor VIII, hemophilia A is a bleeding disorder that affects around 150,000 people worldwide. The condition accounts for over half of all individuals identified with bleeding disorders according to the World Federation of Hemophilia. Approximately 400 males born in Europe annually are diagnosed with hemophilia. Due to important therapeutic implications, routine testing for factor VIII deficiency is required throughout the patient’s life.

"This CE marking represents a major milestone both for our company and for patients with hemophilia A,” stated Dr. Eugene Y. Chan, rHEALTH’s Founder and CEO. “Living with hemophilia is a significant burden for patients and it has been an important focus area in our work towards making diagnostics more accessible. We intend to offer this assay broadly in Europe as we seek additional regulatory approvals elsewhere.”

About rHEALTH

rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes from a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.

*Not available for sale in the USA.

†For research use only. Not for use in diagnostic procedures.

Media Contact

Lillian Li

(617) 913-7630

pr@rhealth.com

rHEALTH Technology Issued New Patent For Optical Block

CAMBRIDGE, Mass., December 5, 2017 - rHEALTH LLC announces the issuance of a new patent in the United States for innovations in optical systems engineering filed by DNA Medicine Institute, DMI. This innovation underscores the portability as well as unique measurement capabilities of the rHEALTH digital diagnostic platform, which represents the miniaturization and automation of traditional laboratory testing technologies as a point-of-care solution.

The U.S. Patent and Trademark Office has granted the patent number 9,835,542, “Optical Block,” for a highly portable and compact, integrated diagnostic system that is designed to measure cells and particles. The unique combination of lasers, detectors, flow channel, lenses, and other electronics within the optical system work to enable precise biomedical measurements. “We are pleased to see this latest patent issuance, which covers one of the core aspects of our diagnostic technology,” said Dr. Eugene Y. Chan, Founder and CEO. “The fundamental aspect of this patent enables our technology to make accurate, precise, and quantitative values possible at point-of-care.”

This new patent expands the companies’ intellectual property portfolio demonstrating DMI and rHEALTH’s ongoing commitment to better care through innovation in portable diagnostics and monitoring technologies.

About rHEALTH

rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.

About DNA Medicine Institute

DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.

Media Contact
Lillian Li

(617) 913-7630

pr@rhealth.com

rHEALTH Technology Issued Three New Patents

rHEALTH LLC announces the issuance of three new patents in the United States for innovations in biochemistry and small volume sample collection filed by DNA Medicine Institute, DMI. These innovations increase the analytic capabilities as well as sophistication of the rHEALTH diagnostic platform, which represents the miniaturization and automation of traditional laboratory testing technologies.

Most recently, the U.S. Patent and Trademark Office (USPTO) has granted the patent number D785,781, “Sample Consumable,” for a design that facilitates micro-volume sampling through capillary action. USTPO has additionally granted the patent number 9,568,425, “Multicoded Analytical Nanostrips,” which covers the improvement of analytical nanostrips for clinical analysis by multifunctional coding. Also granted is the patent number 9,617,383, “PEG-based Microparticles,” which covers the synthesis of monodisperse PEG-based microparticles with stable coupling chemistries.

Added to the spiral vortex micro-mixer technology (US Patent No. 9,194,780), the sample consumable design represents how rHEALTH continues to leverage engineering ingenuity and principles of fluid dynamics to simplify basic steps of microvolume sample collection and processing. “With continued support from NASA, we are excited to offer new solutions that push traditional barriers. Our technology makes massive multiplexing possible in a small volume sample while also providing for measurement of diverse assay types, “said Dr. Eugene Y. Chan, Founder and CEO.

Multicoded nanostrips can simplify assay performance and improve analytic capacity of the rHEALTH device examining small sample volumes. The natural attributes, chemical stability and low autofluorescence, of PEG-based microparticles means that its use allows for better device sensitivity and greater time for sample prep steps. Combined with the flow-cytometry based rHEALTH diagnostic platform, these reagents expand the function of what is traditionally thought possible for a point-of-care testing unit.

These new patents strengthen the companies’ intellectual property as well as confirm DMI and rHEALTH’s strategic commitment to better care through innovation in portable diagnostics and monitoring technologies.

About rHEALTH

rHEALTH is a digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.

About DNA Medicine Institute

DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.

Media Contact
Lillian Li

(617) 913-7630

pr@rhealth.com

rHEALTH Announces Ongoing Collaboration with Bioverativ

rHEALTH LLC, a digital health solutions company and a spin-off of DNA Medicine Institute Inc., today announced that they have an ongoing agreement with Bioverativ Inc., a global biotechnology company focused on rare blood disorders. “We are excited to continue this collaboration with Bioverativ to implement our unique diagnostic technology that may advance the use of the rHEALTH platform,” stated Dr. Eugene Chan, President and CEO. As part of the collaboration, rHEALTH will conduct research on a coagulation assay using its rHEALTH diagnostic platform.

About rHEALTH

rHEALTH is a digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.

About DNA Medicine Institute

DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.

Media Contact

Lillian Li

(617) 913-7630

pr@rhealth.com

rHEALTH Welcomes New VP of Corporate & Business Development

With over 20 years of industry experience, John Adamou is welcomed as a new member of the founding Senior Management Team here at rHEALTH. We are confident that he will advance our mission of empowering health given his established track-record and experience with a range of deal structures across various therapeutic categories including digital health innovation. 

I am delighted to be part of this unique opportunity to increase healthcare accessibility for patients.  I will leverage my experience in global partnering to help bring the rHEALTH technology to patients.   ~ John Adamou

DMI Announces Patent Issuance for rHEALTH ONE

This week, the rHEALTH ONE received a patent issuance from the United States Patent and Trademark Office.  This patent issuance acknowledges the unique design of the biomedical instrument, including its small form factor, novel sample loading mechanism for microvolumes, and low power.  The rHEALTH ONE utilizes the matchbox-sized cytometry module, microparticles, and small volume sample handling to allow a breadth of biomarker and cell analyses.  The patent issuance further strengthens DMI’s intellectual property portfolio for its technology.

Spiral Vortex Micromixer Receives US Patent Issuance

Cambridge, MA – DMI announced today that its spiral vortexer micromixer is now patented.  It formally issued as a patent titled, “Microfluidic Passive Mixing Chip” as US Patent No. 9,194,780.  The patent protects a novel means of mixing large blood cells in a microfluidic environment.  Traditional microfluidic mixers have a difficult time with blood since blood is a lot larger and less diffusion than conventional reagents.  Multiple mixing forces are imparted onto blood samples using the spiral vortexer micromixer.  This technology was developed with support from NASA and has been tested in zero gravity onboard parabolic flights.

NASA Funds DMI for rHEALTH X with Non-Invasive Capabilities

The DNA Medicine Insitute (DMI) announced today that it has been awarded a contract from NASA to develop non-invasive capabilities for the rHEALTH platform. This platform is called the rHEALTH X, which is based on technology to measure a plethora of values from a single drop of blood, bodily fluid, or sample.

“We are thrilled to receive this contract award from NASA and to add non-invasive capabilities to our core rHEALTH technology.  It is our aim to develop a single, handheld device that allows all-encompassing biomedical diagnostic measurements for astronauts for the International Space Station and long-duration space travel to Mars and other challenging destinations.  It is vital that astronauts be able to perform autonomous diagnosis for every possible lab value in order to maximize the probability of mission success.  NASA has been a strong supporter of the technology and we are grateful for the opportunity to develop a technology for our astronauts,” commented Eugene Y. Chan, MD, Principal Investigator of the contract.

In particular, the contract will fund the development of EKG, respiratory rate, SpO2, and temperature measurements.  It is envisioned that the technology will work in conjunction with the rest of the rHEALTH technology, thereby augmenting its capabilities for these important vital signs.